About
RetinAI (operated by Ikerian AG) offers Discovery, an enterprise AI and data management platform designed exclusively for ophthalmology. Healthcare professionals, pharmaceutical companies, and clinical researchers use Discovery to consolidate multimodal retinal imaging data — including OCT volumes, fundus images, DICOM datasets, PDFs, and more — into a single, vendor-neutral cloud environment accessible from anywhere. The platform's CE-MDR certified AI models perform automated layer and fluid segmentation on OCT volumes, delivering rapid volumetric analysis and actionable insights into disease progression, treatment outcomes, and progression prediction. For pharmaceutical and life sciences teams, Discovery accelerates R&D by enabling large-scale data harmonization and real-world evidence generation. Clinics and hospitals benefit from a turnkey tele-ophthalmology solution that centralizes imaging, evaluation, and patient management. Academic and clinical researchers gain real-time collaboration tools with configurable permission levels across global teams. Key capabilities include support for DICOM-compliant and proprietary imaging formats, annotation tools for training custom AI models, secure cloud-based data sharing, and integration-ready APIs. RetinAI has established major partnerships with Boehringer Ingelheim, Retina Consultants of America, the Stephen J. Ryan Initiative for Macular Research (RIMR), and MAXO, positioning it as a leading infrastructure layer for ophthalmic data science and precision medicine.
Key Features
- CE-MDR Certified AI Models: Automated OCT analysis for retinal layer and fluid segmentation, certified for clinical use across EU and international markets.
- Unified Vendor-Neutral Data Platform: Ingest and manage DICOM-compliant, proprietary, JPEG, PNG, TIFF, and PDF imaging data from any device in a single cloud environment.
- Real-World Evidence Generation: Aggregate, harmonize, and analyze imaging data at scale to support pharmaceutical R&D, clinical trials, and regulatory submissions.
- Secure Global Collaboration: Invite collaborators with configurable permission levels for real-time, cross-organizational data sharing and annotation.
- Custom AI Model Training: Extract and export annotations from datasets to build, refine, and deploy proprietary AI models tailored to specific research needs.
Use Cases
- Pharmaceutical companies running clinical studies on geographic atrophy or diabetic retinopathy, using Discovery to manage imaging cohorts and extract AI-driven biomarker insights for regulatory submissions.
- Ophthalmology clinic networks deploying a tele-ophthalmology workflow to remotely evaluate retinal images, centralize OCT data, and monitor patient disease progression over time.
- Academic research consortiums collaborating globally on large-scale retinal imaging datasets for age-related macular degeneration (AMD) studies with secure, permission-controlled data access.
- Medical device manufacturers and AI researchers using the platform's annotation and model-training tools to develop and validate new ophthalmic AI algorithms.
- Hospital systems consolidating fragmented retinal imaging data from multiple imaging devices into a single platform for unified patient record management and AI-assisted diagnostics.
Pros
- Regulatory Compliance Built In: CE-MDR certification for AI models and the ophthalmology data platform provides confidence for clinical deployment and pharmaceutical submissions.
- End-to-End Ophthalmology Workflow: Covers the full pipeline from data ingestion and AI analysis to collaboration and custom model training — eliminating the need for multiple tools.
- Strong Industry Partnerships: Established collaborations with top pharma companies and research institutions validate the platform's capabilities and data interoperability.
Cons
- Ophthalmology-Only Focus: The platform is purpose-built for eye care and retinal imaging, making it unsuitable for other medical specialties or general healthcare use cases.
- Enterprise Pricing Model: Designed for large pharma organizations, hospital networks, and research institutions — pricing and implementation may be out of reach for small independent clinics.
Frequently Asked Questions
What is RetinAI Discovery?
Discovery is RetinAI's flagship AI and data management platform for ophthalmology. It enables healthcare organizations to collect, manage, analyze, and collaborate on retinal imaging data using CE-certified AI models and a secure cloud infrastructure.
Who is RetinAI designed for?
RetinAI serves four main audiences: pharmaceutical and life sciences companies conducting clinical studies, clinics and hospitals managing patient retinal data, clinical and academic researchers building evidence databases, and AI researchers developing ophthalmology models.
What imaging formats does Discovery support?
Discovery is vendor-neutral and supports DICOM-compliant formats, proprietary imaging formats from major device manufacturers, as well as standard image files including JPEG, PNG, TIFF, and PDFs.
Is RetinAI certified for clinical use?
Yes. RetinAI (operated by Ikerian AG) holds EU-MDR certificates for its Ophthalmology Data Platform and multiple AI models. Its co-developed diabetic retinopathy screening algorithm, LuxIA®, received CE-MDR certification in April 2025.
Can organizations train their own AI models on Discovery?
Yes. Discovery includes annotation tools that allow users to label imaging data, export annotations, and use them to train or fine-tune custom AI models tailored to their specific clinical or research objectives.
